The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Inclusion criteria: * Aged ≥ 18 years at the initiation of Atezo/Bev plus HAIC * Initiating Atezo/Bev between 28 October 2020 and 31 June 2025 * Diagnosed with high-risk HCC as evidenced clinically or by radiology, histology or cytology before or at the initiation of Atezo/Bev plus HAIC. The evidence of being diagnosed as "high-risk" was based on the IMbrave 150, including any of the following: * tumor invasion of the main trunk or contralateral branch of the portal vein (Vp4) * bile duct invasion * tumor occupancy of 50% or more of the liver * At least one visit record after the initiation of Atezo/Bev plus HAIC Exclusion criteria: * Diagnosed with concomitant cancer except for basal cell carcinoma before or at the initiation of Atezo/Bev plus HAIC * Participating in interventional clinical studies before or at initiating Atezo/Bev plus HAIC